|
WO1990006952A1
(fr)
*
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
|
WO1995021629A1
(en)
*
|
1994-02-08 |
1995-08-17 |
Amgen Inc. |
Oral delivery of chemically modified proteins
|
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
EP0788375A2
(en)
*
|
1994-11-09 |
1997-08-13 |
Robin Ewart Offord |
Functionalized polymers for site-specific attachment
|
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
|
PT858343E
(pt)
|
1995-11-02 |
2004-07-30 |
Schering Corp |
Terapia por infusao continua de uma dose baixa de citoquina
|
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
|
EP2002846B1
(en)
|
1996-12-06 |
2017-01-25 |
Amgen Inc. |
Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
|
|
DE69800640T2
(de)
*
|
1997-01-29 |
2001-07-05 |
Polymasc Pharmaceuticals Plc, London |
Pegylationsverfahren
|
|
NZ334068A
(en)
|
1997-06-06 |
2000-07-28 |
Kyowa Hakko Kogyo Kk |
Polypeptides chemically modified with polyalkylene glycol derivatives
|
|
EP1881005B1
(en)
*
|
1997-07-14 |
2013-04-03 |
Bolder Biotechnology, Inc. |
Derivatives of G-CSF and related proteins
|
|
US20080076706A1
(en)
*
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
|
EA003789B1
(ru)
*
|
1998-04-28 |
2003-10-30 |
Апплайд Резеч Системз Арс Холдинг Н.В. |
КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
|
|
BR9910505A
(pt)
*
|
1998-05-15 |
2001-01-02 |
Schering Corp |
Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
|
|
NL1009601C2
(nl)
*
|
1998-07-09 |
2000-01-11 |
Univ Utrecht |
Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze.
|
|
WO2000004041A2
(en)
*
|
1998-07-16 |
2000-01-27 |
Hyseq, Inc. |
Methods and molecules relating to cd39-like polypeptides
|
|
DE69925917T2
(de)
*
|
1998-08-06 |
2006-05-11 |
Mountain View Pharmaceuticals, Inc., Menlo Park |
PEG-Urikase Konjugate und Verwendung davon
|
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
|
PT1656952E
(pt)
*
|
1998-10-16 |
2014-02-21 |
Biogen Idec Inc |
Conjugados de polietileno-glicol e interferão beta 1a e as suas utilizações
|
|
AU766190B2
(en)
*
|
1998-10-16 |
2003-10-09 |
Biogen Idec Ma Inc. |
Interferon-beta fusion proteins and uses
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
SK287737B6
(sk)
|
1998-10-23 |
2011-08-04 |
Kirin-Amgen Inc. |
Peptidová zlúčenina, spôsob jej výroby a použitie, farmaceutický prostriedok, polynukleotid, vektor a hostiteľská bunka
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
JP2002531089A
(ja)
*
|
1998-11-30 |
2002-09-24 |
イーライ・リリー・アンド・カンパニー |
赤血球産生性化合物
|
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
KR100731826B1
(ko)
|
1999-01-14 |
2007-06-22 |
볼더 바이오테크놀로지 인코퍼레이티드 |
유리 시스테인 잔기를 함유하는 단백질의 제조 방법
|
|
EP1369429A1
(en)
*
|
1999-01-29 |
2003-12-10 |
F. Hoffmann-La Roche Ag |
GCSF conjugates
|
|
DK1157037T3
(da)
*
|
1999-01-29 |
2003-11-24 |
Hoffmann La Roche |
GCSF-konjugater
|
|
WO2000051626A1
(en)
*
|
1999-03-01 |
2000-09-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Chemically modified g-csf preparations
|
|
US6485718B1
(en)
*
|
1999-04-13 |
2002-11-26 |
Pharmacia Corporation |
Site specific ligation of proteins to synthetic particles
|
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US7160924B2
(en)
*
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
|
US7074878B1
(en)
*
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
|
CZ20022727A3
(cs)
|
2000-01-10 |
2002-11-13 |
Maxygen Holdings Ltd |
Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek
|
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
|
US7049761B2
(en)
*
|
2000-02-11 |
2006-05-23 |
Altair Engineering, Inc. |
Light tube and power supply circuit
|
|
US6806063B2
(en)
|
2000-02-11 |
2004-10-19 |
Maxygen Aps |
Factor VII or VIIa-like molecules
|
|
EP1129720B1
(en)
|
2000-02-29 |
2004-06-23 |
Pfizer Products Inc. |
Stabilized granulocyte colony stimulating factor
|
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
|
WO2001076639A2
(en)
*
|
2000-04-06 |
2001-10-18 |
Pharmacia Corporation |
Chemically-modified myelopoietin conjugates
|
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
|
US6939541B2
(en)
*
|
2000-04-14 |
2005-09-06 |
University Of South Carolina |
Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
|
|
AU5717301A
(en)
|
2000-04-21 |
2001-11-07 |
Amgen Inc |
Apo-ai/aii peptide derivatives
|
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
|
EP1307216A4
(en)
*
|
2000-07-12 |
2005-01-12 |
Gryphon Therapeutics Inc |
MODIFIED POLYMERIC BIOACTIVE SYNTHETIC CHEMOKINES AND METHODS OF MAKING AND USING SAME
|
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
|
AU7338801A
(en)
*
|
2000-09-08 |
2002-03-22 |
Gryphon Sciences |
"pseudo"-native chemical ligation
|
|
US7052686B2
(en)
*
|
2000-09-29 |
2006-05-30 |
Schering Corporation |
Pegylated interleukin-10
|
|
JP5170931B2
(ja)
*
|
2000-10-16 |
2013-03-27 |
中外製薬株式会社 |
Ｐｅｇ修飾エリスロポエチン
|
|
ES2382636T3
(es)
*
|
2000-10-31 |
2012-06-12 |
Surmodics Pharmaceuticals, Inc. |
Método para producir composiciones para la administración mejorada de moléculas bioactivas
|
|
EP1334127A1
(en)
*
|
2000-11-02 |
2003-08-13 |
Maxygen Aps |
Single-chain multimeric polypeptides
|
|
CN1321134C
(zh)
*
|
2000-11-23 |
2007-06-13 |
赵剑 |
一种生物活性蛋白质的非均一制品及其制备方法
|
|
BR0116206A
(pt)
*
|
2000-12-14 |
2003-12-23 |
Amylin Pharmaceuticals Inc |
Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
|
|
US7053150B2
(en)
*
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
|
TW593427B
(en)
*
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
|
ES2361824T3
(es)
*
|
2000-12-20 |
2011-06-22 |
F. Hoffmann-La Roche Ag |
Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
|
|
US7442370B2
(en)
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
|
ATE399794T1
(de)
*
|
2001-02-06 |
2008-07-15 |
Merck Patent Gmbh |
Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
|
|
EP1234583A1
(en)
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-conjugates of HGF-NK4
|
|
EP2080771A3
(en)
|
2001-02-27 |
2010-01-06 |
Maxygen Aps |
New interferon beta-like molecules
|
|
US7276580B2
(en)
|
2001-03-12 |
2007-10-02 |
Biogen Idec Ma Inc. |
Neurotrophic factors
|
|
US20030203865A1
(en)
*
|
2001-04-30 |
2003-10-30 |
Pierrot Harvie |
Lipid-comprising drug delivery complexes and methods for their production
|
|
US7247618B2
(en)
*
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
JP4516719B2
(ja)
|
2001-05-11 |
2010-08-04 |
アムジエン・インコーポレーテツド |
Ｔａｌｌ−１と結合するペプチド及び関連分子
|
|
ATE414711T1
(de)
*
|
2001-06-28 |
2008-12-15 |
Mountain View Pharmaceuticals |
Polymerstabilisierte proteinasen
|
|
HUP0400466A3
(en)
|
2001-07-11 |
2006-01-30 |
Maxygen Holdings Ltd Georgetow |
G-csf conjugates
|
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
|
WO2003030923A1
(en)
*
|
2001-10-05 |
2003-04-17 |
Intermune, Inc. |
Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
|
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
WO2004099231A2
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
|
DK2939696T3
(en)
|
2001-10-18 |
2016-05-23 |
Nektar Therapeutics |
Polymer Conjugates of Opioid Antagonists
|
|
CN100484569C
(zh)
*
|
2001-11-19 |
2009-05-06 |
协和发酵工业株式会社 |
将多潜能干细胞从组织中流通到外周血的药物
|
|
OA13063A
(en)
*
|
2001-11-20 |
2006-11-10 |
Pharmacia Corp |
Chemically-modified human growth hormone conjugates.
|
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
|
KR100480432B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
Ｇ-ｃｓｆ와 폴리에틸렌글리콜 유도체의 배합체
|
|
AU2002346686A1
(en)
*
|
2001-12-07 |
2003-06-23 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
|
DE60323936D1
(de)
*
|
2002-01-14 |
2008-11-20 |
Gen Hospital Corp |
Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
|
|
CN1630530A
(zh)
*
|
2002-01-18 |
2005-06-22 |
比奥根艾迪克Ma公司 |
聚亚烷基聚合物及其用途
|
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
US20030199464A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Silviu Itescu |
Regeneration of endogenous myocardial tissue by induction of neovascularization
|
|
DE60335639D1
(de)
*
|
2002-06-14 |
2011-02-17 |
Amylin Pharmaceuticals Inc |
Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
|
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
|
WO2004009082A1
(en)
|
2002-07-19 |
2004-01-29 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
|
PL376536A1
(pl)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
|
|
NZ538624A
(en)
*
|
2002-09-09 |
2007-01-26 |
Nektar Therapeutics Al Corp |
Water-soluble polymer alkanals
|
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
DE60323756D1
(de)
|
2002-10-08 |
2008-11-06 |
Fresenius Kabi De Gmbh |
Pharmazeutisch aktive oligosaccharid-conjugate
|
|
JP2004196770A
(ja)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
樹状細胞前駆体の血中レベル上昇剤
|
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
|
KR20050090420A
(ko)
|
2002-12-26 |
2005-09-13 |
다케다 야쿠힌 고교 가부시키가이샤 |
메타스틴 유도체 및 이의 용도
|
|
TWI406672B
(zh)
*
|
2002-12-26 |
2013-09-01 |
Mountain View Pharmaceuticals |
生物效力增進的β干擾素聚合物共軛體
|
|
TWI364295B
(en)
*
|
2002-12-26 |
2012-05-21 |
Mountain View Pharmaceuticals |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
|
AU2003303595A1
(en)
*
|
2002-12-30 |
2004-07-29 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
|
US7803362B2
(en)
*
|
2003-01-24 |
2010-09-28 |
Synageva Biopharma Corp. |
Glycosylated interferon alpha
|
|
JP2006519235A
(ja)
*
|
2003-02-26 |
2006-08-24 |
インターミューン インコーポレイティッド |
ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
|
|
WO2004078127A2
(en)
*
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Continuous delivery methods for treating hepatitis virus infection
|
|
ZA200507978B
(en)
|
2003-03-05 |
2007-03-28 |
Halozyme Inc |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
WO2004083258A2
(en)
|
2003-03-14 |
2004-09-30 |
Neose Technologies Inc. |
Branched water-soluble polymers and their conjugates
|
|
WO2004084948A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Biopolymed Inc. |
Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
|
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
|
US7587286B2
(en)
|
2003-03-31 |
2009-09-08 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
US9040664B2
(en)
*
|
2003-04-11 |
2015-05-26 |
Antriabio, Inc. |
Materials and methods for preparing protein-polymer conjugates
|
|
EP2261244A3
(en)
|
2003-04-15 |
2011-02-23 |
Glaxosmithkline LLC |
Human il-18 substitution mutants and their conjugates
|
|
EP1897552B1
(en)
|
2003-04-18 |
2009-06-17 |
Biogen Idec MA Inc. |
Polymer-conjugated glycosylated neublastin
|
|
EP1633317A4
(en)
|
2003-05-16 |
2008-08-20 |
Intermune Inc |
Synthetic chemokine receptor ligands and methods of use therefor
|
|
NZ545009A
(en)
*
|
2003-07-22 |
2009-11-27 |
Nektar Therapeutics Al Corp |
Method for preparing functionalized polymers from polymer alcohols
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
WO2005012530A2
(en)
|
2003-07-25 |
2005-02-10 |
Amgen Inc. |
Antagonists and agonists of ldcam and methods of use
|
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
|
WO2005019260A1
(ja)
*
|
2003-08-25 |
2005-03-03 |
Toray Industries, Inc. |
インターフェロンβ複合体
|
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
|
HRP20171094T1
(hr)
|
2003-09-17 |
2017-10-06 |
Nektar Therapeutics |
Višestruko razgranati polimerni prolijekovi
|
|
JP4704342B2
(ja)
*
|
2003-09-22 |
2011-06-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
|
|
US7230068B2
(en)
|
2003-10-09 |
2007-06-12 |
Ambrx, Inc. |
Polymer derivatives
|
|
ATE481420T1
(de)
|
2003-10-10 |
2010-10-15 |
Novo Nordisk As |
Il-21-derivate
|
|
AU2004279895A1
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc |
Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
|
|
WO2005037214A2
(en)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
|
WO2005040758A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
|
WO2005044836A2
(de)
|
2003-11-05 |
2005-05-19 |
Genovoxx Gmbh |
Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
WO2005053730A1
(ja)
*
|
2003-12-05 |
2005-06-16 |
Kirin Beer Kabushiki Kaisha |
末期心不全治療剤
|
|
WO2005067963A1
(en)
*
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
EP1765853B1
(en)
|
2004-01-08 |
2015-10-28 |
ratiopharm GmbH |
O-linked glycosylation of G-CSF peptides
|
|
JP4682155B2
(ja)
*
|
2004-01-21 |
2011-05-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
|
|
JP4889505B2
(ja)
|
2004-02-02 |
2012-03-07 |
アンブレツクス・インコーポレイテツド |
被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
JP5638177B2
(ja)
|
2004-02-11 |
2014-12-10 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
|
|
NZ579621A
(en)
|
2004-02-11 |
2011-03-31 |
Amylin Pharmaceuticals Inc |
Hybrid polypeptides with selectable properties
|
|
WO2005084303A2
(en)
*
|
2004-03-01 |
2005-09-15 |
Enzon Pharmaceuticals, Inc. |
Interferon-beta polymer conjugates
|
|
MXPA06010764A
(es)
*
|
2004-03-23 |
2006-12-15 |
Amgen Inc |
Metodos y composiciones de proteinas quimicamente modificadas.
|
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
|
BRPI0511196A
(pt)
|
2004-05-19 |
2007-12-04 |
Maxygen Inc |
polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
|
|
US20060018875A1
(en)
*
|
2004-06-14 |
2006-01-26 |
Blatt Lawrence M |
Interferon compositions and methods of use thereof
|
|
WO2006009901A2
(en)
|
2004-06-18 |
2006-01-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
|
AU2005257484A1
(en)
|
2004-06-25 |
2006-01-05 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
|
WO2006004959A2
(en)
*
|
2004-06-30 |
2006-01-12 |
Egen Corporation |
Pegylated interferon alpha-1b
|
|
MX2007000216A
(es)
*
|
2004-07-08 |
2007-03-15 |
Amgen Inc |
Peptidos terapeuticos.
|
|
WO2006010143A2
(en)
*
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
|
KR20070039593A
(ko)
|
2004-07-21 |
2007-04-12 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
|
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
|
UA92590C2
(uk)
|
2004-08-19 |
2010-11-25 |
Байоджен Айдек Ма Інк. |
Варіанти нейбластину
|
|
DE602005022082D1
(de)
|
2004-08-19 |
2010-08-12 |
Biogen Idec Inc |
Rückfaltung von proteinen der transforming-growth-factor-beta-familie
|
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
|
EP1799713B1
(en)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
|
CN101103045B
(zh)
|
2004-09-24 |
2015-11-25 |
安姆根有限公司 |
修饰的Fc分子
|
|
WO2006050247A2
(en)
*
|
2004-10-29 |
2006-05-11 |
Neose Technologies, Inc. |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
US20060153799A1
(en)
*
|
2004-11-05 |
2006-07-13 |
Northwestern University |
Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
|
|
EP1824876B1
(en)
|
2004-12-13 |
2015-07-29 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
CA2590429C
(en)
*
|
2004-12-22 |
2014-10-07 |
Ambrx, Inc. |
Compositions of aminoacyl-trna synthetase and uses thereof
|
|
EP2399893B1
(en)
|
2004-12-22 |
2018-08-15 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
SG161209A1
(en)
|
2004-12-22 |
2010-05-27 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
|
EP1674113A1
(en)
|
2004-12-22 |
2006-06-28 |
F. Hoffmann-La Roche Ag |
Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
|
|
NZ555206A
(en)
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
|
MX2007007580A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Hormona del crecimiento humana modificada.
|
|
NZ556436A
(en)
|
2005-01-10 |
2010-11-26 |
Biogenerix Ag |
Glycopegylated granulocyte colony stimulating factor
|
|
RU2007132188A
(ru)
|
2005-01-25 |
2009-03-10 |
Селл Терапьютикс, Инк. (Us) |
Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo
|
|
EP1854474A4
(en)
*
|
2005-01-31 |
2012-04-04 |
Eci Inc |
IMMUNOSTIMULATING AGENT
|
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
|
MX2007009760A
(es)
|
2005-02-11 |
2007-11-07 |
Amylin Pharmaceuticals Inc |
Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables.
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
WO2006094530A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
|
WO2007010552A2
(en)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
N- terminal peg conjugate of erythropoietin
|
|
NZ561936A
(en)
|
2005-03-31 |
2009-07-31 |
Amylin Pharmaceuticals Inc |
Amylin and amylin agonists for treating psychiatric diseases and disorders
|
|
WO2006105993A2
(en)
|
2005-04-05 |
2006-10-12 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Method for shielding functional sites or epitopes on proteins
|
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
NZ562292A
(en)
|
2005-04-11 |
2009-11-27 |
Savient Pharmaceuticals Inc |
Variant forms of urate oxidase and use thereof
|
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
CN101501068A
(zh)
|
2005-05-18 |
2009-08-05 |
马克西根公司 |
改进的α-干扰素多肽
|
|
EP1891231A4
(en)
|
2005-05-25 |
2011-06-22 |
Novo Nordisk As |
GLYCOPEGYLATED FACTOR IX
|
|
EP1885404A2
(en)
*
|
2005-06-01 |
2008-02-13 |
Alza Corporation |
Bioconjugation reactions for acylating polyethlene glycol reagents
|
|
EP1888119B1
(en)
*
|
2005-06-01 |
2011-03-09 |
Maxygen, Inc. |
Pegylated g-csf polypeptides and methods of producing same
|
|
WO2007009208A1
(en)
*
|
2005-06-02 |
2007-01-25 |
Cangene Corporation |
Poly(ethylene glocol) modified human gm-csf with increased biological activity
|
|
WO2006133089A2
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
|
AU2006257792A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Mdrna, Inc. |
Transmucosal delivery of peptide derivatives
|
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
|
MX2007016068A
(es)
|
2005-06-17 |
2008-03-10 |
Novartis Ag |
Uso de sanglifehrina en hcv.
|
|
CN101257925A
(zh)
*
|
2005-06-20 |
2008-09-03 |
派普根公司 |
人干扰素α类似物和干扰素τ的低毒长循环的嵌合体
|
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
|
US8568705B2
(en)
*
|
2005-07-18 |
2013-10-29 |
Nektar Therapeutics |
Method for preparing branched functionalized polymers using branched polyol cores
|
|
KR100735784B1
(ko)
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
|
MX2008001166A
(es)
|
2005-07-25 |
2008-03-18 |
Intermune Inc |
Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
|
|
WO2007015591A1
(en)
*
|
2005-08-02 |
2007-02-08 |
Cheil Industries Inc. |
Epoxy resin composition for packaging semiconductor device
|
|
MX2008001706A
(es)
*
|
2005-08-04 |
2008-04-07 |
Nektar Therapeutics Al Corp |
Conjugados de una porcion g-csf y un polimero.
|
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
AU2006279680B2
(en)
*
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
DK1937824T3
(da)
|
2005-08-18 |
2013-04-02 |
Ambrx Inc |
Sammensætninger af tRNA og anvendelser deraf
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
US20090239796A1
(en)
|
2005-08-19 |
2009-09-24 |
Amylin Pharmaceuticals, Inc. |
Methods for treating diabetes and reducing body weight
|
|
US8119592B2
(en)
|
2005-10-11 |
2012-02-21 |
Intermune, Inc. |
Compounds and methods for inhibiting hepatitis C viral replication
|
|
WO2007047303A2
(en)
*
|
2005-10-12 |
2007-04-26 |
Alvine Pharmaceuticals, Inc. |
Pegylated glutenase polypeptides
|
|
KR20140077946A
(ko)
|
2005-10-13 |
2014-06-24 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
|
AU2006304856A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Synageva Biopharma Corp. |
Glycolated and glycosylated poultry derived therapeutic proteins
|
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
ATE500215T1
(de)
*
|
2005-11-08 |
2011-03-15 |
Ambrx Inc |
Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
|
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
|
KR20080079643A
(ko)
*
|
2005-11-16 |
2008-09-01 |
암브룩스, 인코포레이티드 |
비-천연 아미노산을 포함하는 방법 및 조성물
|
|
US20080317670A1
(en)
*
|
2005-12-14 |
2008-12-25 |
Ambrx, Inc. |
Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
|
|
US8404643B2
(en)
|
2005-12-22 |
2013-03-26 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
|
BRPI0620819A2
(pt)
|
2005-12-30 |
2011-11-22 |
Zensun Shangai Science & Technology Ltd |
uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
|
|
KR101418607B1
(ko)
|
2006-01-12 |
2014-07-14 |
호쿠산 가부시키가이샤 |
인터페론 α를 포함하는 구강 조성물
|
|
CN100475270C
(zh)
*
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
|
AR059193A1
(es)
|
2006-01-31 |
2008-03-12 |
Bayer Schering Pharma Ag |
Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
|
|
US8309680B2
(en)
|
2006-02-21 |
2012-11-13 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
|
CA2648053A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Centocor, Inc. |
Binding partners with immunoglobulin domains modified to have extended half-life
|
|
KR101059593B1
(ko)
|
2006-04-11 |
2011-08-25 |
노파르티스 아게 |
Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
|
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
|
WO2007133778A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
WO2007136752A2
(en)
|
2006-05-19 |
2007-11-29 |
Glycofi, Inc. |
Erythropoietin compositions
|
|
CA2653154A1
(en)
|
2006-05-24 |
2007-11-29 |
Novo Nordisk Health Care Ag |
Prolonged fix analogues and derivatives
|
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
|
JP2009541333A
(ja)
*
|
2006-06-23 |
2009-11-26 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
修飾リボヌクレアーゼ
|
|
ATE540681T1
(de)
|
2006-06-26 |
2012-01-15 |
Amgen Inc |
Verfahren zur behandlung von atherosklerose
|
|
EP2049151A4
(en)
*
|
2006-07-17 |
2010-03-24 |
Quintessence Biosciences Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
|
CN101516388B
(zh)
*
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
US8299026B2
(en)
*
|
2006-07-25 |
2012-10-30 |
Lipoxen Technologies Limited |
Derivatisation of erythropoietin (EPO)
|
|
GB0615067D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Ttp Communications Ltd |
Reconfigurable signal processing scheme
|
|
PL2054074T3
(pl)
*
|
2006-08-04 |
2015-03-31 |
Prolong Pharmaceuticals Llc |
Zmodyfikowana erytropoetyna
|
|
ITMI20061624A1
(it)
*
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
Mono-coniugati sito-specifici di g-csf
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
CL2007002502A1
(es)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
|
|
CN101484469B
(zh)
*
|
2006-08-31 |
2012-12-12 |
弗·哈夫曼-拉罗切有限公司 |
生产胰岛素样生长因子-ⅰ的方法
|
|
JP5451390B2
(ja)
*
|
2006-09-08 |
2014-03-26 |
アンブルックス，インコーポレイテッド |
脊椎動物細胞内におけるサプレッサーｔｒｎａの転写
|
|
EP2069396B1
(en)
*
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
|
WO2008030613A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
|
NZ597098A
(en)
|
2006-09-28 |
2013-05-31 |
Merck Sharp & Dohme |
Use of pegylated il-10 to treat cancer
|
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー／エス |
ポリペプチドコンジュゲートの精製方法
|
|
RU2460543C2
(ru)
*
|
2006-10-04 |
2012-09-10 |
Ново Нордиск А/С |
Глицерин-связанные пэгилированные сахара и гликопептиды
|
|
US20090252703A1
(en)
*
|
2006-10-19 |
2009-10-08 |
Gegg Jr Colin V |
Use of alcohol co-solvents to improve pegylation reaction yields
|
|
WO2008088422A2
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
JO3048B1
(ar)
|
2006-10-25 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مشتقات متاستين واستخدامها
|
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
|
EP2121743B1
(en)
|
2006-11-22 |
2015-06-03 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
|
ES2618830T3
(es)
|
2006-12-08 |
2017-06-22 |
Lexicon Pharmaceuticals, Inc. |
Anticuerpos monoclonales contra ANGPTL3
|
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
|
CN101245109B
(zh)
*
|
2007-02-12 |
2011-12-14 |
杭州九源基因工程有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
|
|
EP2068909B1
(en)
|
2007-03-30 |
2012-04-25 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
|
WO2008124406A2
(en)
|
2007-04-03 |
2008-10-16 |
Neose Technologies, Inc. |
Methods of treatment using glycopegylated g-csf
|
|
JP2008266219A
(ja)
*
|
2007-04-20 |
2008-11-06 |
National Institute Of Advanced Industrial & Technology |
リジン及びシステイン残基を含まないタンパク質
|
|
ES2476253T3
(es)
|
2007-05-01 |
2014-07-14 |
Biogen Idec Ma Inc. |
P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
|
|
KR20100019467A
(ko)
|
2007-05-02 |
2010-02-18 |
암브룩스, 인코포레이티드 |
변형된 인터페론 베타 폴리펩티드 및 그의 용도
|
|
JP5591691B2
(ja)
|
2007-05-22 |
2014-09-17 |
アムジエン・インコーポレーテツド |
生物活性を有する融合タンパク質を作製するための組成物及び方法
|
|
WO2008151258A2
(en)
*
|
2007-06-04 |
2008-12-11 |
Neose Technologies, Inc. |
O-linked glycosylation using n-acetylglucosaminyl transferases
|
|
ES2551123T3
(es)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Proceso mejorado para la producción de azúcares de nucleótido
|
|
WO2009003188A2
(en)
*
|
2007-06-27 |
2008-12-31 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
|
RS53237B
(sr)
|
2007-07-26 |
2014-08-29 |
Amgen Inc |
Modifikovani enzimi lecitin-holesterol aciltransferaze
|
|
CN101352573B
(zh)
*
|
2007-07-27 |
2011-02-09 |
杭州九源基因工程有限公司 |
聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
|
|
EP2578677A1
(en)
|
2007-08-09 |
2013-04-10 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
|
DK2197919T3
(da)
|
2007-08-27 |
2014-07-07 |
Ratiopharm Gmbh |
Flydende formulering af g-csf-konjugat
|
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
|
US8758761B2
(en)
*
|
2007-09-30 |
2014-06-24 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
|
WO2009048909A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
|
JP5823125B2
(ja)
|
2007-10-23 |
2015-11-25 |
ウェルズ ファーゴ バンク ナショナル アソシエイション |
ヒドロキシアパタイト標的化多腕ポリマーならびに、このポリマーから作られるコンジュゲート
|
|
MX2010005317A
(es)
|
2007-11-20 |
2010-06-02 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
|
CA2707979A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Biovectra Inc. |
Polypeptides modified by protein trans-splicing technology
|
|
ES2428774T3
(es)
|
2007-12-27 |
2013-11-11 |
Baxter International Inc. |
Procedimiento y composiciones para detectar específicamente moléculas poliméricas fisiológicamente aceptables
|
|
US20100316702A1
(en)
*
|
2008-01-08 |
2010-12-16 |
The Regents Of The University Of California |
Compositions and methods for regulating erythropoeitin expression and ameliorating anemia and stimulating erythropoiesis
|
|
EP2242505A4
(en)
*
|
2008-01-08 |
2012-03-07 |
Biogenerix Ag |
GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
|
|
AR070198A1
(es)
|
2008-01-18 |
2010-03-17 |
Biomarin Pharm Inc |
Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos
|
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
|
EP2247743B1
(en)
|
2008-02-08 |
2016-04-06 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
|
WO2009103199A1
(zh)
|
2008-02-18 |
2009-08-27 |
江苏恒瑞医药股份有限公司 |
水溶性聚合物修饰的g-csf偶联物
|
|
EP2626080A3
(en)
|
2008-02-27 |
2014-03-05 |
Novo Nordisk A/S |
Conjugated factor VIII molecules
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
CN101809038B
(zh)
|
2008-04-03 |
2013-10-30 |
厦门伯赛基因转录技术有限公司 |
双链聚乙二醇修饰的生长激素及其制备方法和应用
|
|
WO2009121551A1
(en)
*
|
2008-04-03 |
2009-10-08 |
F. Hoffmann-La Roche Ag |
Pegylated insulin-like-growth-factor assay
|
|
CN103381267A
(zh)
|
2008-04-14 |
2013-11-06 |
哈洛齐梅公司 |
修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
|
WO2009158432A2
(en)
|
2008-06-27 |
2009-12-30 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
NZ600382A
(en)
|
2008-07-23 |
2013-11-29 |
Ambrx Inc |
Modified bovine G-CSF polypeptides and their uses
|
|
WO2010013762A1
(ja)
*
|
2008-07-30 |
2010-02-04 |
武田薬品工業株式会社 |
メタスチン誘導体およびその用途
|
|
NZ591167A
(en)
*
|
2008-07-31 |
2012-06-29 |
Pharmaessentia Corp |
Peptide-polymer conjugates
|
|
US8637466B2
(en)
|
2008-08-11 |
2014-01-28 |
Nektar Therapeutics |
Multi-arm polymeric alkanoate conjugates
|
|
EP2331139B1
(en)
|
2008-09-11 |
2019-04-17 |
Nektar Therapeutics |
Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
|
|
DK2342223T3
(en)
|
2008-09-26 |
2017-07-24 |
Ambrx Inc |
Modified animal erythropoietin polypeptides and their uses
|
|
MX357314B
(es)
|
2008-09-26 |
2018-07-04 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
|
BRPI0920743A2
(pt)
|
2008-10-01 |
2016-09-20 |
Quintessence Biosciences Inc |
ribonucleases terapeuticas
|
|
EA032727B1
(ru)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Мутантный резистентный к протеолизу полипептид fgf21 и его применение
|
|
JP4966434B2
(ja)
|
2008-10-15 |
2012-07-04 |
バクスター・インターナショナル・インコーポレイテッド |
結合抗体の存在下における組換え血液凝固因子のｐｅｇ化
|
|
CA2738679A1
(en)
|
2008-10-17 |
2010-04-22 |
Baxter International Inc. |
Modified blood factors comprising a low degree of water soluble polymer
|
|
EP2337794B1
(en)
|
2008-10-20 |
2013-07-31 |
USV Limited |
An improved process for pegylation of proteins
|
|
EP2350658A2
(en)
*
|
2008-10-21 |
2011-08-03 |
Baxter International Inc. |
Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
|
|
AU2009308909A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Amgen Inc. |
Materials and methods relating to stem cell mobilization by multi-PEGylated granulocyte colony stimulating factor
|
|
IT1392655B1
(it)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
Site-specific monoconjugated insulinotropic glp-1 peptides.
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
|
|
PT3037529T
(pt)
|
2008-12-09 |
2019-05-31 |
Halozyme Inc |
Polipéptidos ph20 estendidos solúveis e suas utilizações
|
|
US20100152115A1
(en)
*
|
2008-12-11 |
2010-06-17 |
Baxter International Inc. |
Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
|
|
JP5888980B2
(ja)
|
2008-12-17 |
2016-03-22 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
モノ−およびジ−ｐｅｇｉｌ１０の製造および用途
|
|
WO2010117957A2
(en)
|
2009-04-06 |
2010-10-14 |
Mayo Foundation For Medical Education And Research |
Methods and materials for delivering molecules
|
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
|
EP2427207B1
(en)
|
2009-05-05 |
2017-08-16 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
|
MY156542A
(en)
|
2009-05-05 |
2016-02-26 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
|
PT3175863T
(pt)
|
2009-05-20 |
2022-01-20 |
Biomarin Pharm Inc |
Variantes do péptido natriurético de tipo c
|
|
JP2012530493A
(ja)
|
2009-06-17 |
2012-12-06 |
アムジエン・インコーポレーテツド |
キメラポリペプチドおよびその使用
|
|
KR20120112350A
(ko)
|
2009-06-19 |
2012-10-11 |
메디뮨 엘엘씨 |
프로테아제 변이체
|
|
BRPI1010069A2
(pt)
|
2009-06-25 |
2016-03-15 |
Savient Pharmaceuticals Inc |
"método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
|
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
|
JP5734985B2
(ja)
|
2009-09-17 |
2015-06-17 |
バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ |
ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
WO2011037896A2
(en)
*
|
2009-09-25 |
2011-03-31 |
Vybion, Inc. |
Polypeptide modification
|
|
CN102597775A
(zh)
|
2009-09-25 |
2012-07-18 |
佐马技术有限公司 |
筛选方法
|
|
WO2011050938A1
(de)
|
2009-10-26 |
2011-05-05 |
Genovoxx Gmbh |
Konjugate von nukleotiden und methoden zu deren anwendung
|
|
NZ598465A
(en)
|
2009-10-30 |
2013-10-25 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
|
NZ599543A
(en)
|
2009-10-30 |
2014-02-28 |
Ntf Therapeutics Inc |
Improved neurturin molecules
|
|
EP2504021A4
(en)
|
2009-11-23 |
2013-05-15 |
Amylin Pharmaceuticals Llc |
Polypeptide conjugate
|
|
BR112012012983A2
(pt)
|
2009-12-04 |
2020-09-15 |
Genentech Inc |
método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
PE20121799A1
(es)
|
2009-12-21 |
2013-01-02 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos
|
|
EP2805964A1
(en)
|
2009-12-21 |
2014-11-26 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
|
US20110152188A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Hanns-Christian Mahler |
Pharmaceutical compositions of igf/i proteins
|
|
US20130040888A1
(en)
|
2010-02-16 |
2013-02-14 |
Novo Nordisk A/S |
Factor VIII Molecules With Reduced VWF Binding
|
|
KR101857825B1
(ko)
*
|
2010-03-04 |
2018-05-14 |
피페넥스 인크. |
변성 없이 가용성 재조합 인터페론 단백질을 제조하는 방법
|
|
CA2794740C
(en)
|
2010-04-01 |
2019-12-31 |
Pfenex Inc. |
Methods for g-csf production in a pseudomonas host cell
|
|
WO2011130417A2
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
|
|
EP2563380B1
(en)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
|
JP6294074B2
(ja)
|
2010-04-27 |
2018-03-14 |
エータイアー ファーマ， インコーポレイテッド |
イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
AU2011248489B2
(en)
|
2010-04-28 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
|
|
JP5991963B2
(ja)
|
2010-04-29 |
2016-09-14 |
エータイアー ファーマ， インコーポレイテッド |
バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
US8986680B2
(en)
|
2010-04-29 |
2015-03-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
|
|
CN102234310B
(zh)
*
|
2010-04-30 |
2017-02-08 |
杭州九源基因工程有限公司 |
一种聚乙二醇修饰蛋白的分离纯化方法
|
|
EP2566515B1
(en)
|
2010-05-03 |
2017-08-02 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
|
WO2011140135A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
|
US9034321B2
(en)
|
2010-05-03 |
2015-05-19 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
|
|
AU2011248101B2
(en)
|
2010-05-04 |
2016-10-20 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
|
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
|
CN103200953B
(zh)
|
2010-05-14 |
2017-02-15 |
Atyr 医药公司 |
与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
EP2571896A4
(en)
|
2010-05-17 |
2014-01-08 |
Cebix Inc |
PEGYLATED C-PEPTIDE
|
|
CA2799480C
(en)
|
2010-05-17 |
2020-12-15 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
|
|
ES2573108T3
(es)
|
2010-05-26 |
2016-06-06 |
Bristol-Myers Squibb Company |
Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
|
|
JP6046607B2
(ja)
|
2010-05-27 |
2016-12-21 |
エータイアー ファーマ， インコーポレイテッド |
グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
CN103118694B
(zh)
|
2010-06-01 |
2016-08-03 |
Atyr医药公司 |
与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
|
CN102711871A
(zh)
|
2010-06-16 |
2012-10-03 |
麦德托尼克公司 |
用于稳定药物递送装置中的药物的阻尼系统
|
|
CA2803093A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
|
CN103118695B
(zh)
|
2010-07-12 |
2016-08-03 |
Atyr医药公司 |
与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
|
US20130183280A1
(en)
|
2010-07-15 |
2013-07-18 |
Novo Nordisk A/S |
Stabilized factor viii variants
|
|
WO2012012300A2
(en)
|
2010-07-20 |
2012-01-26 |
Halozyme, Inc. |
Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
|
|
AR082319A1
(es)
|
2010-07-22 |
2012-11-28 |
Biomarin Pharm Inc |
Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2446173C1
(ru)
*
|
2010-08-13 |
2012-03-27 |
Зао "Биокад" |
Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
|
|
SMT202400182T1
(it)
|
2010-08-17 |
2024-07-09 |
Ambrx Inc |
Polipeptidi di relaxina modificati e loro usi
|
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
|
US9029506B2
(en)
|
2010-08-25 |
2015-05-12 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases
|
|
CN103209992A
(zh)
|
2010-09-15 |
2013-07-17 |
诺沃—诺迪斯克有限公司 |
具有减少的细胞摄取的因子viii变体
|
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
|
ES2630031T3
(es)
|
2010-09-28 |
2017-08-17 |
Aegerion Pharmaceuticals, Inc. |
Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
|
|
WO2012045704A1
(en)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
New treatments of hepatitis c virus infection
|
|
CN103179966B
(zh)
|
2010-10-08 |
2017-03-15 |
诺瓦提斯公司 |
磺酰胺ns3抑制剂的维生素e制剂
|
|
CN102453089B
(zh)
*
|
2010-10-25 |
2014-06-04 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
|
CN103933577B
(zh)
*
|
2010-10-25 |
2014-12-10 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
|
CN103298490B
(zh)
|
2010-11-24 |
2017-04-26 |
莱克康制药公司 |
结合背板胶质乙酰酯酶的抗体
|
|
CN105381450A
(zh)
|
2010-11-30 |
2016-03-09 |
诺华有限公司 |
丙型肝炎病毒感染的新疗法
|
|
CN102485742A
(zh)
*
|
2010-12-02 |
2012-06-06 |
山东新时代药业有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
|
|
US20140371258A1
(en)
|
2010-12-17 |
2014-12-18 |
Nektar Therapeutics |
Water-Soluble Polymer Conjugates of Topotecan
|
|
US10736969B2
(en)
|
2010-12-21 |
2020-08-11 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
|
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
|
JP2014509859A
(ja)
|
2011-03-16 |
2014-04-24 |
アムジエン・インコーポレーテツド |
１７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
|
|
CA2830664A1
(en)
*
|
2011-03-25 |
2012-10-04 |
The Trustees Of Columbia University In The City Of New York |
Pegylated human hdl particle and process for production thereof
|
|
AU2012233644A1
(en)
|
2011-03-31 |
2013-09-12 |
Novartis Ag |
Alisporivir to treat Hepatitis C virus infection
|
|
RU2013148779A
(ru)
|
2011-04-01 |
2015-05-10 |
Новартис Аг |
Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
|
|
EP2696883A1
(en)
|
2011-04-13 |
2014-02-19 |
Novartis AG |
Treatment of hepatitis c virus infection with alisporivir
|
|
EP2709669A1
(en)
|
2011-05-17 |
2014-03-26 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
|
EA201990698A1
(ru)
|
2011-06-03 |
2019-12-30 |
Ксома Текнолоджи Лтд. |
Антитела, специфические к tgf-бета
|
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
EP2720713A2
(en)
|
2011-06-17 |
2014-04-23 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
|
|
RU2654231C2
(ru)
|
2011-06-28 |
2018-05-17 |
Алтернатив Инновейтив Текнолоджиз, Ллц |
Способ применения белков теплового шока-70 (бтш70) для повышения выносливости и лечения бтш70-зависимых заболеваний (варианты)
|
|
CA2840552A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
|
HUE029855T2
(en)
|
2011-07-05 |
2017-04-28 |
Bioasis Technologies Inc |
p97 antibody conjugates
|
|
PT2729160T
(pt)
|
2011-07-08 |
2019-07-08 |
Aegerion Pharmaceuticals Inc |
Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida
|
|
CN102952067A
(zh)
*
|
2011-08-30 |
2013-03-06 |
苏州欣诺科生物科技有限公司 |
用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用
|
|
JP2014526441A
(ja)
|
2011-08-31 |
2014-10-06 |
アムジエン・インコーポレーテツド |
１型糖尿病の治療における使用のためのｆｇｆ２１
|
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
|
UY34346A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de fusión para tratar trastornos metabólicos
|
|
MX2014003753A
(es)
|
2011-09-27 |
2014-05-01 |
Novartis Ag |
Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c.
|
|
WO2013056197A1
(en)
|
2011-10-14 |
2013-04-18 |
Alternative Innovative Technologies Llc |
Degradation resistant hsp70 formulations and uses thereof
|
|
JP6162707B2
(ja)
|
2011-10-24 |
2017-07-12 |
ハロザイム インコーポレイテッド |
抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
|
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
|
US9241869B2
(en)
|
2011-10-25 |
2016-01-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
WO2013067029A2
(en)
|
2011-10-31 |
2013-05-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
|
WO2013075117A2
(en)
|
2011-11-17 |
2013-05-23 |
John Wahren |
Pegylated c-peptide
|
|
RU2685867C2
(ru)
|
2011-12-15 |
2019-04-23 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
|
|
DK3130347T3
(da)
|
2011-12-30 |
2019-10-14 |
Halozyme Inc |
PH20-polypeptidvarianter, formuleringer og anvendelser deraf
|
|
CN104203282A
(zh)
|
2012-01-30 |
2014-12-10 |
艾瑞克有限公司 |
稳定的水性抗体组合物
|
|
IN2014MN01642A
(enExample)
|
2012-02-16 |
2015-07-03 |
Atyr Pharma Inc |
|
|
EA037979B1
(ru)
|
2012-02-27 |
2021-06-18 |
Амуникс Оперейтинг Инк. |
Композиции конъюгата xten и способы их получения
|
|
AU2013226944B2
(en)
|
2012-02-29 |
2017-03-23 |
Toray Industries, Inc. |
Inhibitory agent for body cavity fluid accumulation
|
|
WO2013134138A1
(en)
|
2012-03-03 |
2013-09-12 |
Immungene, Inc. |
Engineered antibody-interferon mutant fusion molecules
|
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
|
CN104411332B
(zh)
|
2012-03-30 |
2018-11-23 |
索伦托治疗有限公司 |
与vegfr2结合的全人抗体
|
|
LT2833905T
(lt)
|
2012-04-04 |
2018-07-10 |
Halozyme, Inc. |
Derinių terapija su hialuronidaze ir į naviką nukreiptu taksanu
|
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
HK1208236A1
(en)
|
2012-06-22 |
2016-02-26 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind ccr2
|
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
CN104662150B
(zh)
|
2012-07-31 |
2018-07-10 |
比奥阿赛斯技术有限公司 |
脱磷酸化的溶酶体贮积症蛋白及其使用方法
|
|
WO2014036492A1
(en)
|
2012-08-31 |
2014-03-06 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
WO2014074218A1
(en)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
|
KR20150085064A
(ko)
|
2012-11-16 |
2015-07-22 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
단백질 화학적 변형을 위한 피크테 스펭글러 결합
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
|
ES2875957T3
(es)
|
2012-12-20 |
2021-11-11 |
Amgen Inc |
Agonistas del receptor APJ y usos de los mismos
|
|
CN103908660B
(zh)
*
|
2013-01-05 |
2015-02-04 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法
|
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
|
CN103113466B
(zh)
*
|
2013-03-01 |
2015-06-03 |
中国科学院过程工程研究所 |
聚乙二醇修饰的重组人干扰素β-1b及制备方法
|
|
WO2014165277A2
(en)
|
2013-03-12 |
2014-10-09 |
Amgen Inc. |
POTENT AND SELECTIVE INHIBITORS OF Nav1.7
|
|
JP6586412B2
(ja)
|
2013-03-13 |
2019-10-02 |
バイオアシス テクノロジーズ インコーポレイテッド |
ｐ９７のフラグメントおよびその使用
|
|
RU2535002C2
(ru)
*
|
2013-04-04 |
2014-12-10 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук |
Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
|
|
WO2014172392A1
(en)
|
2013-04-18 |
2014-10-23 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9823255B2
(en)
|
2013-06-17 |
2017-11-21 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
EP3336103B1
(en)
|
2013-07-10 |
2021-03-17 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
EP3038657A2
(en)
|
2013-08-28 |
2016-07-06 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
CA2920679A1
(en)
|
2013-08-30 |
2015-03-05 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
EP3052123A1
(en)
|
2013-10-02 |
2016-08-10 |
Novartis Ag |
Insulin-like growth factor mimetics for use in therapy
|
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
WO2015057908A1
(en)
|
2013-10-18 |
2015-04-23 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
|
MX2016005915A
(es)
|
2013-11-11 |
2016-12-16 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
|
EP3068891A1
(en)
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Engineered glycoproteins and uses thereof
|
|
WO2015081282A1
(en)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
|
UY35874A
(es)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
Un proceso para la preparación de una composición de proteínas pegiladas
|
|
WO2015130963A2
(en)
|
2014-02-27 |
2015-09-03 |
Xenetic Biosciences, Inc. |
Compositions and methods for administering insulin or insulin-like protein to the brain
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
US10941182B2
(en)
|
2014-06-10 |
2021-03-09 |
Amgen Inc. |
Apelin polypeptides
|
|
KR101981532B1
(ko)
|
2014-06-12 |
2019-09-02 |
라 파마슈티컬스 인코포레이티드 |
보체 활성의 조절
|
|
SG11201701382PA
(en)
|
2014-08-22 |
2017-03-30 |
Sorrento Therapeutics Inc |
Antigen binding proteins that bind cxcr3
|
|
ES2727137T3
(es)
|
2014-08-28 |
2019-10-14 |
Halozyme Inc |
Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
|
|
US10350270B2
(en)
|
2014-10-14 |
2019-07-16 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
CA3126536C
(en)
|
2014-10-14 |
2023-07-25 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
WO2016064817A1
(en)
|
2014-10-22 |
2016-04-28 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
EP3412302B1
(en)
|
2014-10-24 |
2021-05-12 |
Bristol-Myers Squibb Company |
Modified fgf-21 polypeptides and uses thereof
|
|
KR102540109B1
(ko)
|
2014-11-06 |
2023-06-02 |
파마에센시아 코퍼레이션 |
Peg화된 인터페론의 투약 요법
|
|
US20160151511A1
(en)
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
|
CN104491843B
(zh)
*
|
2015-01-23 |
2017-09-12 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG‑CSF活性药物组合物
|
|
WO2016123371A1
(en)
|
2015-01-28 |
2016-08-04 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
|
CN107849108A
(zh)
*
|
2015-03-03 |
2018-03-27 |
阿瓦隆生物制品有限公司 |
聚乙二醇化的il‑11的组合物和方法
|
|
EP3277716B1
(en)
|
2015-04-03 |
2020-06-24 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
JP6525171B2
(ja)
|
2015-04-13 |
2019-06-05 |
国立研究開発法人産業技術総合研究所 |
環状化サイトカイン及びその製法
|
|
AU2016257724B2
(en)
|
2015-05-01 |
2021-02-25 |
Allysta Pharmaceuticals, Inc. |
Adiponectin peptidomimetics for treating ocular disorders
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
KR20180020141A
(ko)
|
2015-05-28 |
2018-02-27 |
아르모 바이오사이언시스 인코포레이티드 |
암 치료에 사용되는 peg화된 인터류킨-10
|
|
EP3331562A2
(en)
|
2015-08-06 |
2018-06-13 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
|
JP7053453B2
(ja)
|
2015-08-25 |
2022-04-12 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を治療するためのインターロイキン１０の使用方法
|
|
SG10202008963QA
(en)
*
|
2015-09-18 |
2020-10-29 |
Univ Miyazaki |
Long-acting adrenomedullin derivative
|
|
CA3000697A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
|
US10935276B2
(en)
|
2015-10-20 |
2021-03-02 |
Steven Michalski |
Air mixing device
|
|
IL259186B2
(en)
|
2015-11-09 |
2023-03-01 |
Scherer Technologies Llc R P |
Anti-cd22-maytensin antibody conjugates and methods of using them
|
|
MX2018006986A
(es)
|
2015-12-08 |
2018-09-05 |
Biomarin Pharm Inc |
Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.
|
|
TWI745320B
(zh)
|
2015-12-16 |
2021-11-11 |
美商Ｒａ製藥公司 |
補體活性之調節劑
|
|
US10118963B2
(en)
|
2016-01-29 |
2018-11-06 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
KR102331668B1
(ko)
|
2016-04-15 |
2021-11-25 |
베크만 컬터, 인코포레이티드 |
광활성 거대분자 및 그의 용도
|
|
JP7148493B2
(ja)
|
2016-08-01 |
2022-10-05 |
ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー |
副甲状腺ホルモン受容体１（ｐｔｈ１ｒ）抗体およびその使用
|
|
KR20190057113A
(ko)
|
2016-09-28 |
2019-05-27 |
조마 (유에스) 엘엘씨 |
인터루킨-2에 결합하는 항체 및 그 용도
|
|
JP2019535819A
(ja)
|
2016-11-11 |
2019-12-12 |
ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ |
プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
|
|
US20200237881A1
(en)
|
2019-01-30 |
2020-07-30 |
Horizon Pharma Rheumatology Llc |
Reducing immunogenicity to pegloticase
|
|
JP7301741B2
(ja)
|
2016-12-07 |
2023-07-03 |
ラ ファーマシューティカルズ インコーポレイテッド |
補体活性のモジュレータ
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
BR112019016139A2
(pt)
|
2017-02-08 |
2020-04-07 |
Bristol-Myers Squibb Company |
polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
|
|
CA3177086A1
(en)
|
2017-06-22 |
2018-12-27 |
Catalyst Biosciences, Inc. |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
|
KR102020995B1
(ko)
|
2017-10-30 |
2019-09-16 |
한국코러스 주식회사 |
콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
|
|
US11492493B2
(en)
|
2017-12-26 |
2022-11-08 |
Becton, Dickinson And Company |
Deep ultraviolet-excitable water-solvated polymeric dyes
|
|
JP2021509805A
(ja)
|
2017-12-27 |
2021-04-08 |
カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ |
顆粒球コロニー刺激因子活性を示すポリペプチド
|
|
WO2019178374A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Ba Yong |
Pegylated antifreeze proteins and methods of making and using the same
|
|
WO2019191482A1
(en)
|
2018-03-30 |
2019-10-03 |
Becton, Dickinson And Company |
Water-soluble polymeric dyes having pendant chromophores
|
|
EP3784209A1
(en)
|
2018-04-24 |
2021-03-03 |
Amgen Inc. |
Method for making injectable pharmaceutical compositions
|
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
|
EP3813867A1
(en)
|
2018-07-22 |
2021-05-05 |
Bioasis Technologies Inc. |
Treatment of lymmphatic metastases
|
|
HRP20240016T1
(hr)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Konjugati polipeptida interleukina-2 i njihove uporabe
|
|
WO2020082057A1
(en)
|
2018-10-19 |
2020-04-23 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
|
PH12021551405A1
(en)
|
2018-12-28 |
2022-05-11 |
Vertex Pharma |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
WO2020160322A1
(en)
|
2019-01-30 |
2020-08-06 |
Horizon Pharma Rheumatology Llc |
Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
|
|
JP7695885B2
(ja)
|
2019-02-12 |
2025-06-19 |
アンブルックス，インコーポレイテッド |
抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
|
|
US10882954B2
(en)
|
2019-04-11 |
2021-01-05 |
Sunbio Inc. |
Tertiary alkoxy polyethylene glycol and derivatives thereof
|
|
WO2020213015A1
(en)
*
|
2019-04-15 |
2020-10-22 |
Nof Corporation |
Conjugate of bio-related substance and block polymer, and block polymer derivative for obtaining said conjugate
|
|
WO2020214690A1
(en)
|
2019-04-15 |
2020-10-22 |
Qwixel Therapeutics |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
MX2022011163A
(es)
|
2020-03-11 |
2022-10-18 |
Ambrx Inc |
Conjugados de polipeptidos de interleucina-2 y sus usos.
|
|
EP4121448A2
(en)
|
2020-03-20 |
2023-01-25 |
Amgen Inc. |
Determination of free n-terminus of pegfilgrastim using an acid protease
|
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
|
US11602598B1
(en)
|
2020-08-27 |
2023-03-14 |
Fresenius Kabi Deutschland Gmbh |
Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
|
|
CN112710826A
(zh)
*
|
2020-11-17 |
2021-04-27 |
北京九强生物技术股份有限公司 |
一种提高试剂稳定性的包被和封闭方法
|
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|
|
CN113214328B
(zh)
*
|
2021-05-08 |
2022-06-28 |
宁波经济技术开发区弘翔生化科技有限公司 |
一种双水相体系以及基于双水相体系的单糖分离方法
|
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
|
AU2023298234A1
(en)
|
2022-07-01 |
2025-01-16 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|
|
WO2024196805A1
(en)
|
2023-03-17 |
2024-09-26 |
Beckman Coulter, Inc. |
Benzothienopyrrole cyanine dyes
|
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|
|
WO2025064842A1
(en)
|
2023-09-21 |
2025-03-27 |
Beckman Coulter, Inc. |
Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
|
|
WO2025227129A2
(en)
|
2024-04-25 |
2025-10-30 |
Starrock Pharma Llc |
Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
|
|
US20250341516A1
(en)
|
2024-05-01 |
2025-11-06 |
BioLegend, Inc. |
Compositions for use with multiple fluorophores and methods of using
|